Tempus AI Past Earnings Performance
Past criteria checks 0/6
Tempus AI's earnings have been declining at an average annual rate of -24.5%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 31.2% per year.
Key information
-24.5%
Earnings growth rate
-18.9%
EPS growth rate
| Life Sciences Industry Growth | 21.5% |
| Revenue growth rate | 31.2% |
| Return on equity | -1,383.4% |
| Net Margin | -125.0% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Tempus AI: Pioneering The Future Of Precision Medicine Through AI-Driven Innovation
Nov 12Tempus: Attempting To Lead The AI Revolution In Healthcare
Oct 29Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
Aug 21Tempus AI: Healthcare AI Play Faces Some Challenges From The Start
Jun 14Revenue & Expenses Breakdown
How Tempus AI makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 640 | -801 | 729 | 304 |
| 30 Jun 24 | 596 | -790 | 699 | 293 |
| 31 Mar 24 | 562 | -293 | 307 | 193 |
| 31 Dec 23 | 532 | -266 | 297 | 178 |
| 30 Sep 23 | 485 | -276 | 276 | 172 |
| 31 Dec 22 | 321 | -334 | 237 | 162 |
| 30 Sep 22 | 293 | -325 | 222 | 156 |
| 31 Dec 21 | 258 | -298 | 194 | 128 |
| 30 Sep 21 | 285 | -296 | 180 | 118 |
| 30 Jun 21 | 284 | -286 | 161 | 110 |
| 31 Mar 21 | 236 | -270 | 142 | 101 |
| 31 Dec 20 | 188 | -254 | 124 | 91 |
| 31 Dec 19 | 62 | -148 | 79 | 57 |
Quality Earnings: TEM is currently unprofitable.
Growing Profit Margin: TEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TEM is unprofitable, and losses have increased over the past 5 years at a rate of 24.5% per year.
Accelerating Growth: Unable to compare TEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TEM is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).
Return on Equity
High ROE: TEM has a negative Return on Equity (-1383.41%), as it is currently unprofitable.